Boletín de Farmacia
Agosto 2020


En la selección de artículos colaboró la Dra. Cristina Fernández Barrantes

 

AMERICAN JOURNAL OF HEALTH SYSTEM  PHARMACY   2020   77 (12)

1.     A multicenter quality improvement initiative on the impact of pharmacists’ postdischarge follow-up toreduce medication-related acute care episodes. Pág. 938-942.

2.     Evaluating the effects of a multidisciplinary transition care management program on hospital readmissions. Pág. 931-937.

3.     Effects of pharmacy interventions at transitions of care on patient outcomes. Pág. 943-949.

4.     Evaluation of a multidisciplinary approach to reduce internal medicine readmissions using a readmission prediction index. Pág. 950-957.

5.     Improving transitions of care for critically ill adult patients on pulmonary arterial hypertension medications. Pág. 958-965.

6.     Pharmacist-led transitions-of-care program reduces 30-day readmission rates for Medicare patients in a large health system. Pág. 972-978.


AMERICAN JOURNAL OF HEALTH SYSTEM  PHARMACY   2020   77 (11)

7.   Therapeutic monitoring of vancomycin for serious methicillin-resistant staphylococcus aureus infections : a revised consensus guideline and review by the American Society of Health-System Pharmacists, the infectious diseases society of America the Pediatric Infections Disease Society, and the society of infectious diseases pharmacists. Pág . 835-863.

8.   Direct-acting oral anticoagulant use at extremes of body weight: Literature review and recommendations. Pág. 865-876.

9.   Pharmacokinetics of linezolid for methicillin-resistant Staphylococcus aureus pneumonia in an adult receiving extracorporeal membrane oxygenation .Pág. 877-881.

 AMERICAN JOURNAL OF HEALTH SYSTEM  PHARMACY   2020   77 (9)

10.  Long-term stability of ready-to-use 1-mg/mL midazolam solution. Pág. 681-689.

 

11.  Safety of intravenous push administration of beta-lactams within a healthcare system. Pág.    701-708.

 
AMERICAN JOURNAL OF HEALTH SYSTEM  PHARMACY   2020   77 (10)

12.  A physician-pharmacist collaborative care model to prevent opioid misuse 771-780

13.  Procalcitonin in special patient populations: Guidance for antimicrobial therapy. Pág. 745-758.

14.  Involvement of pharmacist-reviewed urine cultures and sexually transmitted infections in the emergency department reduces time to antimicrobial optimization. Pág. Supl 2. S54-S59.

 
COVID-19 AMERICAN JOURNAL OF HEALTH SYSTEM  PHARMACY

15.  Implementation of field hospital pharmacy services during the COVID-19 pandemic.

16.  Maintaining comprehensive pharmacy services during a pandemic: recommendations from a designated COVID-19 facility.

17.  COVID-19 pandemic preparedness: A practical guide from an operational pharmacy perspective.

18.  Pharmacy services at a temporary COVID-19 hospital in Wuhan, China.

19.  Surviving the surge: Evaluation of early impact of COVID-19 on inpatient pharmacy services at a community teaching hospital.

20.  Minimizing pharmacotherapy-related healthcare worker exposure to SARS-CoV-2.


21.  Establishing clinical pharmacist telehealth services during the COVID-19 pandemic.

 

22.  COVID-19 pandemic planning, response, and lessons learned at a community hospital.

 

23. Assessment of Evidence for COVID-19-Related Treatments: Updated

 
 

CURRENT OPINION PHARMACOLOGY   2020   53

24. Potential of glucocorticoids to treat intestinal inflammation during sepsis. Pág.1-7.

25. Impact of gut microbiota on neurogenesis and neurological diseases during infancy. Pág. 33-37.

26. Anti-inflammatory glucocorticoid action: genomic insights and emerging concepts. Pág. 35-44.


CURRENT OPINION PHARMACOLOGY   2020   50

27. Endocannabinoid system and adult neurogenesis: a focused review. Pág. 25-32.

 

NEW ENGLAND JOURNAL OF MEDICINE  2020 382 (23)

 
28. Enzalutamide and Survival in Nonmetastatic,Castration-Resistant Prostate Cancer. Pág. 2197-2206

 

NEW ENGLAND JOURNAL OF MEDICINE  2020 382 (24)

 

29 .Compassionate Use of Remdesivir for Patients with Severe Covid-19 Pág. 2327-2336.

      30. Disseminated Coccidioidomycosis Treated with Interferon-γ and Dupilumab. Pág.2337-2336